Skip to main content
. 2023 Jan 18;15(3):591. doi: 10.3390/cancers15030591

Table 2.

Pain prevalence in treatment-naïve cancer patients (Group 1) (n = 20).

% Pain
Study Quality Continent a Setting b Cancer c Mean Age Sample None Mild Moderate ModSev d Severe Overall
Alt-Epping, 2016 [33] 16 2 2 60.6 22 22.7 18.2 45.5 59.1 13.6 77.3
Andersen, 2014 [34] 16 2 2 5 133 60 7 37
Bibby, 2019 [35] 15 2 2 11 64 229 43.7
Efficace, 2015 [36] 16 1,2,3 2 10 70.02 280 45 43.2 11.8 55
Esser, 2017 [37] 15 2 2 10 50.4 239 15
Gjeilo, 2020 [38] 18 2 1,2 4 65.8 264 60 40
Godby–a, 2021 [39]
Godby–b, 2021 [39]
18
18
1
1
2
2
6
6
70
70
46
309
75.6
40.7
Hong, 2015 [40] 15 3 1 6 62.18 165 62.4
Kirchheiner, 2015 [41] 17 2 2 9 50 6.0
Kuon, 2019 [42] 17 2 2 4 63.6 208 34.6
Lunde, 2019 [43] 18 2 2 9 67.2 207 16.9
Ravn Munkvold, 2018 [44] 18 2 1 2 507 48 30 12 22 10 52
Roy, 2016 [45] 16 3 2 4 56.4 36 47.2
Russo, 2018 [46] 17 2 2 2 52.7 527 12.5
Salwey, 2020 [47] 19 2 2 60 26.7 20 53.3 73.3
Tang, 2015 [48] 18 6 1 11 55.1 91 46.8 21.1 63.2
Thomas, 2017 [49] 15 1 2 1 66 105 63
Wang, 2021 [50] 16 3 2 5 50.99 88 4.5
Williams, 2021 [51] 15 1 2 6 70.1 364 45.1
Yao, 2020 [52] 15 1 2 7 83 69.2 23.1 5.8 7.7 1.9 30.8

a 1 = North America; 2 = Europe; 3 = Asia; 4 = South America; 5 = Africa; 6 = Australia/New Zealand; b 1 = inpatient; 2 = outpatient; 3 = patient in a palliative care setting; 4 = all; 5 = other; c 1 = >3 types of cancer; 2 = head and neck; 3 = oesophagus, 4 = bronchus/lung; 5 = breast; 6 = gastro-intestinal; 7 = prostate; 8 = other, urological; 9 = gynaecological; 10 = haematological; 11 = other; d moderate–severe pain.